Skip to main content
. Author manuscript; available in PMC: 2024 May 13.
Published in final edited form as: Nat Microbiol. 2023 May 4;8(6):1108–1122. doi: 10.1038/s41564-023-01380-4

Figure 5. Human sera contains antibodies that partially cross-neutralize MBaMV.

Figure 5.

a) MeV, MBaMV, and CDV were incubated with serial dilutions of pooled human sera from MMR-vaccinated individuals (MMR group 1 and group 2) and sera from ferrets infected with CDV. The capacity for sera-treated virus to infect Vero cells expressing the appropriate receptor was measured by imaging infected cells 20 hpi, measuring the area of GFP+ cells, and calculating the reduction in infection compared to no sera controls. Neutralization curves were plotted for each virus and corresponding sera group. b) The IC50s from the neutralization curves shown in a) were generated for each replicate using a robust fit model and were plotted. Two independent experiments were completed with the pooled human sera neutralization and one experiment with technical duplicates was completed using the CDV sera (mean +/− S.D.). P values were calculated with a one-way ANOVA using a Tukey’s multiple comparisons test.